SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: 8-K
Document Type: EX-10.1
Date Filed: 2026-03-25
Accession Number: 0001213900-26-034072
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390026034072/ea028322301ex10-1.htm

Chunk 66 of 68
Word Count: 1202
Character Count: 7387

Document Content:

purchase the remaining Shares or other securities purchasable under this Warrant, which new warrant shall, in all other respects, be identical to this Warrant. The Company shall take all actions as may be necessary to ensure that the Warrant Stock issuable upon exercise of this Warrant is issued without violation by the Company of its organizational documents, any applicable law or governmental regulations. The Company shall pay all expenses in connection with, and all taxes (excluding taxes based on income) and other governmental charges that may be imposed with respect to, the issuance or delivery of the Warrant Stock upon exercise of this Warrant. If an exercise by Holder is for less than all of the Warrant Stock purchasable under this Warrant, the Company will as soon as reasonably practicable deliver to Holder a new Warrant or Warrants of like tenor, for the balance of the Warrant Stock purchasable hereunder.

6.2 Holder’s
Exercise Limitations. Until and unless Stockholder Warrant Approval is obtained, the Company shall not issue shares of Common Stock
issuable upon exercise of this Warrant to the extent that after giving effect to such issuance after exercise, the Holder (together with
the Holder’s affiliates, and any other persons acting as a group together with the Holder or any of the Holder’s affiliates),
would beneficially own in excess of 19.9% of the number of shares of the Common Stock outstanding immediately after giving effect to
the applicable issuance of shares of Common Stock issuable upon such exercise of this Warrant (calculated in accordance with Section
13(d) of the Exchange Act and the rules and regulations promulgated thereunder) (the “Beneficial Ownership Limitation”).
For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its affiliates shall
include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being
made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised
portion of this Warrant beneficially owned by the Holder or any of its affiliates and (ii) exercise or conversion of the unexercised
or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
affiliates. Upon the written or oral request of a Holder, the Company shall within one (1) business day confirm orally and in writing
to the Holder the number of shares of Common Stock then outstanding. If on any attempted exercise of this Warrant, the issuance of Warrant
Stock would exceed the amount of shares of Common Stock permitted by this Section 6.2, then the Company shall issue to Holder such number
of Warrant Stock as may be issued pursuant to this Section 6.2. The limitations contained in this paragraph shall apply to a successor
holder of this Warrant.

6.3 Stockholder
Warrant Approval. The Company covenants to seek stockholder approval of the exercise of this Warrant for any amount in excess of
the Beneficial Ownership Limitation (the “Stockholder Warrant Approval”) at the next annual meeting of stockholders,
which shall be held no later than June 30, 2026. The Company shall seek the Stockholder Warrant Approval in accordance with applicable
law, the rules and regulations of the NASDAQ Stock Market, the Company’s certificate of incorporation and bylaws and Chapter 78
of the Nevada Revised Statutes, and the Company shall use its reasonable best efforts to solicit the Stockholder Warrant Approval and
to cause the board of directors of the Company to recommend to the Company stockholders that they approve the Stockholder Warrant Approval.

Net Issue Election.

7.1. Right
to Convert. In addition to and without limiting the rights of the Holder under the terms of this Warrant, after a Qualified Event
of Default, the Holder shall have the right to convert this Warrant or any portion hereof (the “Conversion Right”)
into shares of Warrant Stock as provided in this Section 7. Upon exercise of the Conversion Right with respect to a particular number
of shares subject to this Warrant (the “Converted Warrant Shares”), the Company shall deliver to the Holder (without
payment by the Holder of any cash or other consideration) that number of shares of Warrant Stock equal to the quotient obtained by dividing
(x) the value of this Warrant (or the specified portion hereof) on the Conversion Date (as defined in subsection 7.2 hereof), which value
shall be determined by subtracting (A) the aggregate Warrant Price of the Converted Warrant Shares immediately prior to the exercise
of the Conversion Right from (B) the aggregate Market Price of the Converted Warrant Shares issuable upon exercise of this Warrant (or
the specified portion hereof) on the Conversion Date by (y) the Market Price of one share of Warrant Stock on the Conversion Date. No
fractional shares shall be issuable upon exercise of the Conversion Right, and if the number of shares to be issued determined in accordance
with the foregoing formula is other than a whole number, the Company shall pay to the Holder an amount in cash in lieu of such fractional
share as set forth in Section 3.

7.2. Method
of Exercise. The Conversion Right may be exercised by the Holder by the surrender of this Warrant at the principal office of the
Company together with a written statement specifying that the Holder thereby intends to exercise the Conversion Right and indicating
the number of shares subject to this Warrant that are being surrendered (referred to in subsection 7.1 hereof as the Converted Warrant
Shares) in exercise of the Conversion Right. Such conversion shall be effective upon such surrender of this Warrant (the “Conversion
Date”). The Company shall cause its transfer agent to issue and deliver to the person or entity entitled to receive the same,
the shares of Warrant Stock issuable upon exercise of the Conversion Right (or any other securities deliverable in lieu thereof under
Section 2).

7.3. Determination
of Fair Market Value. For purposes of this Section 7, fair market value (the “Market Price”) of a share of Common
Stock or, if different, Warrant Stock as of a particular date shall mean the official Nasdaq closing price of the Common Stock on the
day of exercise, or, if on any day such security is not so listed, the average of the highest bid and lowest asked prices on such day
in the domestic over-the-counter market as reported by the National Quotation Bureau, Incorporated, or any similar successor organization.
If at any time such security is not listed on any securities exchange or the over-the-counter market, the “Market Price”
shall be the fair market value thereof as determined in good faith by the Company’s Board of Directors.

8. Certificate
of Adjustment. Whenever the Warrant Price or number or type of securities issuable upon exercise of this Warrant is adjusted, as
herein provided, the Company shall promptly deliver to the record holder of this Warrant a certificate of an officer of the Company setting
forth the nature of such adjustment and a brief statement of the facts requiring such adjustment.